Drug companies keeping trial info under wraps
Eli Lilly has made a point of registering all but its smallest drug trials at clinicaltrials.gov, as promised, but many other drug companies persist in holding back much of their trial information. The New York Times looks at how Merck, Pfizer, GlaxoSmithKline and other drug giants have been reluctant players in the push for more transparency in drug trials. In some cases, the companies refuse to reveal even the name of the drug under investigation. The latest push for transparency began after a series of revelations that drug companies had hidden data that raised safety questions regarding some of their most popular medications.
- read this story from The New York Times on the trials
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


